A Novel δ-Hemolysis Screening Method for Detecting Heteroresistant Vancomycin-Intermediate Staphylococcus aureus and Vancomycin-Intermediate S. aureus | Zendy

Viviana Cafiso | Zendy; Taschia Bertuccio | Zendy; Daniela Spina | Zendy; Simona Purrello | Zendy; G Blandino | Zendy; Stefania Stefani | Zendy

Open Access

A Novel δ-Hemolysis Screening Method for Detecting Heteroresistant Vancomycin-Intermediate Staphylococcus aureus and Vancomycin-Intermediate S. aureus

Author(s) -

Viviana Cafiso,

Taschia Bertuccio,

Daniela Spina,

Simona Purrello,

G Blandino,

Stefania Stefani

Publication year - 2012

Publication title -

journal of clinical microbiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.349

H-Index - 255

eISSN - 1070-633X

pISSN - 0095-1137

DOI - 10.1128/jcm.06307-11

Subject(s) - staphylococcus aureus , vancomycin , hemolysis , microbiology and biotechnology , micrococcaceae , staphylococcal infections , medicine , antibacterial agent , antibiotics , bacteria , biology , immunology , genetics

We assessed a new screening method, based on δ-hemolysin production in the presence of 6 mg/liter vancomycin, to distinguish heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) and vancomycin-intermediate S. aureus (VISA) from vancomycin-susceptible S. aureus (VSSA). On 37 clinical methicillin-resistant S. aureus (MRSA) isolates, hVISA and VISA displayed no δ-hemolysis whereas VSSA displayed strong δ-hemolysis, showing 91.6% sensitivity. These data, supported by real-time reverse transcription PCR (real-time RT-PCR) highlighting an hld downregulation, i.e., VSSA>hVISA>VISA, define this new assay as a valid screening method.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research